Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Conditions
Keywords
Advanced, Metastatic, Refractory, Anti-CD73, Checkpoint immunotherapies, PD-1/PD-L1 inhibitors
Brief summary
This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1 inhibitor or chemotherapy.
Detailed description
Mavrostobart (PT199) is an anti-CD73 mAb with a differentiated mechanism of action and is expected to completely inhibit CD73 enzyme activity. Mavrostobart (PT199) is designed to counter the adenosine-mediated immunosuppressive tumor microenvironment, rendering anti-tumor immune cells to be more active and more responsive to checkpoint immunotherapies, such as PD-1/PD-L1 inhibitors. CD73 is widely overexpressed in a number of different cancers, including pancreatic ductal adenocarcinoma (PDAC), gastric carcinoma, colorectal carcinoma, non-small cell lung cancer (NSCLC), sarcomas and glioblastomas. Thus, targeting CD73 may provide benefit for patients with a high CD73 expression in their tumor. Mavrostobart (PT199) addresses the limitations of current CD73 inhibitors and is expected to increase antitumor immune activation, especially in combination with PD-1 pathway inhibition, and thus offer a new treatment option for cancer patients. NSCLC is known to have a high expression level of CD73, and emerging clinical data has shown that targeting CD73 may provide clinical benefit, when combined with an immune checkpoint inhibitor (ICI) and/or standard of care chemotherapies to overcome treatment resistance.
Interventions
DRUGMavrostobart (PT199)
Mavrostobart (PT199) is an anti-CD73 mAb with a differentiated mechanism of action.
DRUGTislelizumab
Anti-PD-1 monoclonal antibody 200 mg Q3W, inhibits the lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response.
Dosing is per Standard of Care.
DRUGDocetaxel
Dosing is per Standard of Care.
DRUGPemetrexed
Dosing is per Standard of Care.
DRUGGemcitabine
Dosing is per Standard of Care.
DRUGCarboplatin + Pemetrexed
Dosing is per Standard of Care.
Dosing is per Standard of Care.
Sponsors
BeiGene
Phanes Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
The study will consist of 4 parts: Monotherapy Dose Escalation (Part A), ICI Combination Therapy Dose Escalation (Part B), ICI Combination Dose Expansion in NSCLC (Part C), and Combination with Chemotherapy in frontline (1L) PDAC patients (Part D).
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria 1. At least one measurable lesion as defined by RECIST V1.1 criteria for solid tumors. 2. For Part A: a histologically or cytologically confirmed unresectable advanced or metastatic solid tumors previously treated with therapies, or for which treatment is not available or not tolerated. For Part B: A histologically or cytologically confirmed diagnosis of NSCLC without actionable genomic alterations (AGAs) such as EGFR or ALK mutations and radiological documentation of disease progression on prior treatments, which may include a checkpoint inhibitor, or patients diagnosed with metastatic and/or advanced (m/a) PDAC who have disease progression after previously treated with therapies, or for which treatment is not available or not tolerated. For Part C: A histologically or cytologically confirmed diagnosis of NSCLC without actionable genomic alterations such as EGFR or ALK mutations and radiological documentation of disease progression on prior treatments, which may include a checkpoint inhibitor. For Part D: * Cohort D1: a histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma (PDAC), treatment naïve for advanced or metastatic disease, and eligible to receive standard of care treatment with gemcitabine plus nab-paclitaxel. * Cohort D2: a histologically or cytologically confirmed diagnosis of NSCLC without actionable genomic alterations (AGAs) such as EGFR or ALK mutations and radiological documentation of disease progression on prior treatments, which may include a checkpoint inhibitor. Patients have progressed under first-line (1L) SOC chemotherapy with or without ICI or later lines of therapy, or for which standard 1L therapy has proven to be ineffective, intolerable, or is considered inappropriate. * Cohort D3: a histologically or cytologically confirmed diagnosis of NSCLC without actionable genomic alterations (AGAs) such as EGFR or ALK mutations. Patients are treatment naïve and have no contra indication to receive carboplatin plus pemetrexed. * Cohort D4: a histologically or cytologically confirmed diagnosis of NSCLC without actionable genomic alterations (AGAs) such as EGFR or ALK mutations. Patients are treatment naïve and are eligible for 1L therapy with pembrolizumab and carboplatin plus pemetrexed. 3. In all Parts, should be able to provide a tumor tissue sample (archival or newly acquired biopsy) to be assessed for CD73 and other biomarkers (PD-L1), unless deemed by the Investigator to cause risk to the patient or per Investigator's discretion. 4. ECOG performance status of 0 or 1. 5. Adequate organ function confirmed at screening and within 72 hours of initiating treatment. Key
Exclusion criteria
1. Women who are pregnant or lactating. 2. Women of child-bearing potential (WOCBP) who do not use adequate birth control. 3. Autoimmune disease requiring systemic treatment within the past twelve months. Active autoimmune disease or a history of autoimmune diseases that may relapse. 4. Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days prior to study treatment. 5. Patients who have experienced Grade ≥ 3 immune-related events, such as (non-infectious) pneumonitis, interstitial lung disease, myocarditis. 6. Patients with untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed. 7. Impaired cardiac function or significant diseases. 8. Patients who have ≥ Grade 3 neuropathy. 9. Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from adverse events of prior therapy. 10. Patients who are currently receiving (last dose within 5 days from C1D1) treatment with therapeutic doses of warfarin sodium (Coumadin®) or any other coumarin-derivative anticoagulants. Additional inclusion and
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the maximum tolerated dose (MTD), if reached. | Start of the study drug till 90 days after last dose. |
| Recommended Phase 2 Dose of Mavrostobart (PT199) as a single agent and/or in combination with a PD-1 inhibitor. | Start of the study drug till 90 days after last dose. |
| Dose Limiting Toxicity (DLT). | Time Frame: Start of the study drug till 90 days after last dose. |
Secondary
| Measure | Time frame |
|---|---|
| Half Life (T1/2) of Mavrostobart (PT199) | Time Frame: Start of the study drug till 90 days after last dose. |
| Preliminary efficacy assessed by the response rate by RECIST 1.1 for disease control rate. | Time Frame: Start of the study drug till 90 days after last dose. |
| Preliminary efficacy assessed by the response rate by RECIST 1.1 for overall response rate. | Start of the study drug till 90 days after last dose. |
| 6-month overall survival. | Time Frame: Start of the study drug till 90 days after last dose. |
| Progression free survival duration. | Time Frame: Start of the study drug till 90 days after last dose. |
| Area Under the Curve from time 0 to last (AUC0-last) of Mavrostobart (PT199) | Time Frame: Start of the study drug till 90 days after last dose. |
| Maximum Concentration (Cmax) of Mavrostobart (PT199) | Time Frame: Start of the study drug till 90 days after last dose. |
Countries
United States
Contacts
Primary ContactPhanes Therapeutics
Outcome results
None listed